Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
3'-Phosphoadenosine 5'-phosphosulphate:
galactosylceramide sulfotransferase
which catalyzes the sulfation of galactosylceramide (GalCer) was partially purified from a rat kidney light membrane fraction, and the properties were studied with special reference to substrate specificity. In order to study minimum molecular requirement of the acceptor substrate for the sulfotransferase, analogues of galactosylceramide where omega-amiocaproic or omega-aminododecanoic acid is substituted for the acyl moiety of the native glycolipid were chemically synthesized by improved procedures. The artificial glycolipids were sulfated effectively by the kidney enzyme, suggesting that the synthetic compounds will serve for affinity ligands for the purification of the enzyme. The extent of sulfation in the synthetic compounds was comparable with that of galactosylceramide containing normal acids and higher than that of galactosylsphingonine in which one of hydrocarbon chains is deleted from the native glycolipid. Through substrate specificity experiments, the sulfotransferase has relatively broad specificity acting on beta-linked galactosides at nonreducing ends of mono- and disaccharides which bind, at least, one hydrocarbon chain. Enzyme kinetic analysis by competition assay using mixed acceptors demonstrated that the same, single sulfotransferase catalyzes sulfation of galactosylceramide, lactosylceramide and galactosylsphingosine. As to human cancer, the sulfotransferase activity was hardly detectable in Wilms' tumor tissues that contrasts with renal cell carcinoma tissues where the markedly elevated level was previously demonstrated. When sera from patients with various cancers were examined for the enzyme level, many cases of
hepatocellular carcinoma
showed significantly increased activity, whereas the
hepatoma
tissues had hardly detectable level of the enzyme. These observations suggest that a humoral factor derived from the
hepatoma
induces the sulfotransferase.
...
PMID:[Characterization of glycolipid sulfotransferase fractionated from rat kidney and involvement of the enzyme in human cancer]. 133 Aug 60
Activity of
glycolipid sulfotransferase
(cerebroside sulfotransferase) in serum was elevated in 21 (33%) of 63 patients with
hepatocellular carcinoma
(
HCC
, mean +/- S.E., 349 +/- 32 pmol/ml per h, n = 63, P less than 0.001) compared to healthy subjects (172 +/- 12, n = 85). Ho significant elevation of the sulfotransferase level was observed in liver cirrhosis (219 +/- 28, n = 10) in which many of biochemical
HCC
markers increase concomitantly. The elevation of sulfotransferase was independent of the production of alpha-fetoprotein and of aminotransferase levels in
HCC
, providing complementary value for alpha-fetoprotein-negative
HCC
cases. However, the sulfotransferase levels (234 +/- 21, n = 32, P less than 0.01) in sera from patients with renal cell carcinoma, in whose involved tissues the enzyme was demonstrated to increase markedly, were less than in
HCC
.
...
PMID:Elevated serum level of glycolipid sulfotransferase in patients with hepatocellular carcinoma. 171 32